MedDRA preferred term

Seasonal allergy: adverse event reports recording this term

13,923 reports to FDA record it, 2004–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

13,923
reports recording the term: 0.1% of all reports; 1,025
reports, 12 months to June 2026: 1,291 in the 12 months before; 47.3%
marked serious by the reporter: 57.4% across all reports; 1.4%
record death among outcomes, as reported: 9.1% across all reports

"Seasonal allergy" is a MedDRA preferred term recorded in 13,923 adverse event reports received by FDA, 0.1% of the database, from March 2004 to June 2026. The term is chosen by whoever codes the report to match what the reporter described.

1,025 reports recorded it in the 12 months to June 2026, down 21% from 1,291 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 47.3% are marked serious, 1.4% include death among the outcomes and 19.1% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Revlimid, Humira and Dupixent. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Revlimid	Thalidomide analog	810	0.2%
Humira	—	638	0.1%
Dupixent	Interleukin-4 receptor alpha antagonist	510	0.1%
Tyvaso	Prostacycline vasodilator	487	1.7%
Enbrel	Tumor necrosis factor blocker	484	0.1%
Human immunoglobulin g	Human immunoglobulin G	469	2.7%
Tyvaso DPI	Prostacycline vasodilator	455	4.9%
Xolair	Anti-IgE	424	0.7%
Remodulin	Prostacycline vasodilator	376	0.8%
Xyrem	Central nervous system depressant	326	0.5%
Xeljanz	Janus kinase inhibitor	321	0.2%
Prednisone	Corticosteroid	300	0.2%
Orenitram	Prostacycline vasodilator	283	1.7%
Entresto	Angiotensin 2 receptor blocker	245	0.2%
Omalizumab	Anti-IgE	235	2.3%
Opsumit	Endothelin receptor antagonist	209	0.5%
Symbicort	Corticosteroid	170	0.4%
Cosentyx	Interleukin-17A antagonist	164	0.1%
Tysabri	Integrin receptor antagonist	150	0.1%
Singulair	Leukotriene receptor antagonist	137	0.7%
Actemra	Interleukin-6 receptor antagonist	136	0.2%
Ambrisentan	Endothelin receptor antagonist	133	0.2%
Pomalyst	Thalidomide analog	132	0.2%
Methotrexate	Folate analog metabolic inhibitor	131	0.1%
Fosamax	Bisphosphonate	128	0.4%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Prostacycline vasodilator	1,770	1.5%	1.5%
Corticosteroid	996	0.1%	0%
Thalidomide analog	978	0.2%	0.2%
Tumor necrosis factor blocker	793	0.1%	0%
Anti-IgE	665	0.8%	0.7%
Human immunoglobulin G	577	0.8%	0.1%
Endothelin receptor antagonist	533	0.3%	0.2%
Kinase inhibitor	530	0.1%	0%
Interleukin-4 receptor alpha antagonist	526	0.1%	0.1%
Janus kinase inhibitor	449	0.1%	0%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.1%16

2 to 111.2%171

12 to 170.9%131

18 to 4410.6%1,475

45 to 6423.3%3,240

65 to 7413.1%1,818

75 and over6.2%869

Age not given44.6%6,203

Patient sex

Female66.2%9,219

Male27%3,755

Not given6.8%949

Grey bar: all 20,646,523 reports in the database. 82.8% of these reports give the United States as the country.

Questions about "Seasonal allergy"

What does "Seasonal allergy" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record seasonal allergy?

13,923 reports through June 2026 (0.1% of all reports), 1,025 of them in the latest 12 months.

Which drugs appear most often in these reports?

Revlimid (810), Humira (638), Dupixent (510), Tyvaso (487) and Enbrel (484). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.